About Bacil Pharma Ltd
Data last updated:
Bacil Pharma Ltd is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 08 May 1987 and has been in existence for over 39 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24200MH1987PLC043427. The company has 1 GST registration on record, which is no longer active. Its shares are listed on BSE: 524516.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14.35 Cr. It is led by directors including Chaitali Kalpataru Shah and Omprakash Pyarelal Sonar.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mumbai, Maharashtra.
The net worth stands at ₹24.81 Cr (down 2.4% YoY). Total assets are valued at ₹24.81 Cr (down 3.1% YoY).
The company is associated with 1 brand: Bacil Pharma.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bacilpharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressOffice G2/G3 Samarpan Complex Next To Mirador Hotel, Link Road Opp Satam Wadi Chakala Sahar Andheri (East), Mumbai, Maharashtra, India – 400099
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands with Bacil Pharma Ltd
Bacil Pharma operates one associated brand: Bacil Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of drugs | bacilpharma.com |
Auditor Details of Bacil Pharma Ltd
Bacil Pharma Ltd is audited by Laxmikant Kabra & Co. LLP for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| Laxmikant Kabra & Co. LLP | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Bacil Pharma Ltd
Bacil Pharma has 3 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chaitali Kalpataru Shah | Additional Director | 16 Jul 2025 | 1 Years 2 Months | Current |
| Omprakash Pyarelal Sonar Also directs: Goodspark Trading Private Limited | Additional Director | 30 Jun 2026 | 0 Years 3 Months | Current |
| Vivek Mukesh Yadav Also directs: Briya Enterprise Limited | Additional Director | 30 Jun 2026 | 0 Years 3 Months | Current |
Financials of Bacil Pharma Ltd FY 2025-26 filings available
Bacil Pharma Ltd reported revenue of ₹- for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | (0.24) | (0.25) | (0.18) | (0.22) | (3.91) | (0.30) | (0.43) |
| Profit before tax | 1.00 | 0.41 | (0.05) | (0.11) | (3.85) | (0.23) | (0.31) |
| Net profit | 1.57 | (0.13) | (0.15) | (0.16) | (0.09) | (0.09) | (0.05) |
| EPS (₹) | 1.11 | 0.29 | (0.09) | (0.16) | (5.91) | (0.37) | (0.48) |
| Balance sheet | |||||||
| Total assets | 24.81 | 25.60 | 1.31 | 1.12 | 1.26 | 1.57 | 1.56 |
| Net worth | 24.81 | 25.43 | 1.22 | 1.10 | 1.23 | 1.39 | 1.39 |
| Total debt | 0.00 | 0.16 | 0.10 | 0.02 | 0.03 | 0.18 | 0.17 |
| Cash & bank | 0.57 | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 |
| Net working capital | (0.83) | 2.90 | 0.03 | 0.03 | 0.23 | (2.36) | (2.45) |
| Cash flow | |||||||
| Cash from operations | 0.71 | 0.40 | 0.00 | (0.15) | (4.01) | (0.40) | (0.38) |
| Cash from investing | (2.38) | 0.34 | 0.08 | (0.12) | 3.81 | 0.53 | 0.39 |
| Cash from financing | (0.62) | 2.08 | (0.06) | 0.06 | 0.33 | (0.07) | (0.06) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.09 | 0.11 | 0.06 | 0.05 | 1.00 | 0.09 | 0.00 | 0.56 |
| Total expenses | 0.02 | 0.07 | 0.03 | 0.04 | 0.11 | 0.07 | 0.06 | 0.07 |
| EBITDA | (0.02) | (0.07) | (0.03) | (0.04) | (0.11) | (0.07) | (0.06) | (0.07) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.07 | 0.04 | 0.03 | 0.01 | 0.89 | 0.02 | (0.06) | 0.49 |
| Tax | 0.08 | (0.58) | 0.00 | 0.00 | 0.22 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.09 | 0.11 | 0.06 | 0.05 | 1.00 | 0.09 | 0.00 | 0.56 |
| Total expenses | 0.02 | 0.07 | 0.03 | 0.04 | 0.11 | 0.07 | 0.06 | 0.07 |
| EBITDA | (0.02) | (0.07) | (0.03) | (0.04) | (0.11) | (0.07) | (0.06) | (0.07) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.07 | 0.04 | 0.03 | 0.01 | 0.89 | 0.02 | (0.06) | 0.49 |
| Tax | 0.08 | (0.58) | 0.00 | 0.00 | 0.22 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 1.24 | 0.66 | 0.13 | 0.11 | 0.06 | 0.07 | 0.14 |
| Total expenses | 0.24 | 0.25 | 0.18 | 0.22 | 3.91 | 0.30 | 0.43 |
| Employee cost | 0.05 | 0.14 | 0.10 | 0.09 | 0.06 | 0.05 | 0.09 |
| EBITDA | (0.24) | (0.25) | (0.18) | (0.22) | (3.91) | (0.30) | (0.43) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Profit before tax | 1.00 | 0.41 | (0.05) | (0.11) | (3.85) | (0.23) | (0.31) |
| Tax | (0.57) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | 1.57 | (0.13) | (0.15) | (0.16) | (0.09) | (0.09) | (0.05) |
| EPS (₹) | 1.11 | 0.29 | (0.09) | (0.16) | (5.91) | (0.37) | (0.48) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 13.97 | 13.97 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 |
| Reserves & surplus | 10.84 | 11.46 | (5.31) | (5.43) | (5.30) | (5.14) | (5.14) |
| Shareholders' funds (net worth) | 24.81 | 25.43 | 1.22 | 1.10 | 1.23 | 1.39 | 1.39 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.18 | 0.17 |
| Unsecured loans | 0.00 | 0.16 | 0.10 | 0.02 | 0.00 | 0.00 | 0.00 |
| Total debt | 0.00 | 0.16 | 0.10 | 0.02 | 0.03 | 0.18 | 0.17 |
| Total liabilities | 24.81 | 25.60 | 1.31 | 1.12 | 1.26 | 1.57 | 1.56 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 0.06 | 0.06 | 0.06 | 2.56 | 2.56 |
| Net block | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 2.52 | 2.52 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 24.24 | 21.36 | 0.61 | 0.43 | 0.31 | 0.37 | 0.43 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 1.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | 0.57 | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 |
| Loans & advances | 0.00 | 0.05 | 0.01 | 0.01 | 0.01 | 0.06 | 0.06 |
| Total current assets | 1.75 | 2.91 | 0.05 | 0.04 | 0.24 | 0.16 | 0.10 |
| Total current liabilities | 2.58 | 0.01 | 0.02 | 0.01 | 0.01 | 2.52 | 2.55 |
| Net working capital | (0.83) | 2.90 | 0.03 | 0.03 | 0.23 | (2.36) | (2.45) |
| Total assets | 24.81 | 25.60 | 1.31 | 1.12 | 1.26 | 1.57 | 1.56 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 | 0.09 |
| Net cash from operating activities | 0.71 | 0.40 | 0.00 | (0.15) | (4.01) | (0.40) | (0.38) |
| Net cash from investing activities | (2.38) | 0.34 | 0.08 | (0.12) | 3.81 | 0.53 | 0.39 |
| Net cash from financing activities | (0.62) | 2.08 | (0.06) | 0.06 | 0.33 | (0.07) | (0.06) |
| Net change in cash | (2.29) | 2.82 | 0.01 | (0.20) | 0.13 | 0.06 | (0.05) |
| Closing cash | 0.57 | 2.86 | 0.04 | 0.03 | 0.23 | 0.10 | 0.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| EBITDA growth | +4.0% | -38.9% | +18.2% | +94.4% | -1203.3% | +30.2% | - |
| PBT growth | +143.9% | +9998.0% | +54.6% | +97.1% | -1573.9% | +25.8% | +13.9% |
| Net income growth | +1307.7% | +13.3% | +6.3% | -77.8% | 0.0% | -80.0% | - |
| EBITDA CAGR (3Y) | +2.9% | -60.0% | -15.7% | -20.0% | +107.1% | -57.8% | +36.3% |
| Profitability & leverage | |||||||
| Return on capital employed | +3.9% | -1.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | +6.2% | -1.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | 0.00 | 0.01 | 0.05 | 0.02 | 0.08 | 0.13 | 0.08 |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.27 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | 1.11 | 0.29 | (0.09) | (0.16) | (5.91) | (0.37) | (0.48) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 17.76 | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 | 2.12 |
Shareholding Pattern of Bacil Pharma Ltd
Shareholding for the quarter ended Mar 2026: promoters hold 0.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 100.00%.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 0.00% | 0.10% | 0.10% | 0.20% |
| Public | 100.00% | 99.90% | 99.90% | 99.80% |
Charges & Borrowings of Bacil Pharma Ltd
Bacil Pharma Ltd does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Bacil Pharma Ltd
Employment history and EPFO contributions of people linked to Bacil Pharma.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Bacil Pharma Ltd
Bacil Pharma has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Bacil Pharma Ltd
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Bacil Pharma Ltd
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Bacil Pharma Ltd
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Bacil Pharma Ltd
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Bacil Pharma Ltd
Frequently Asked Questions about Bacil Pharma Ltd
Bacil Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 08 May 1987 (39+ years old) and is registered under CIN L24200MH1987PLC043427. Listed on BSE: 524516.
Bacil Pharma has 3 current directors:
- Chaitali Kalpataru Shah - Additional Director
- Omprakash Pyarelal Sonar - Additional Director
- Vivek Mukesh Yadav - Additional Director
No. Bacil Pharma has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Bacil Pharma is L24200MH1987PLC043427. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Bacil Pharma is listed on BSE with code 524516.
Bacil Pharma was incorporated on 08 May 1987, making it 39+ years old. It is registered with the Registrar of Companies, Mumbai.
Bacil Pharma can be reached through the website bacilpharma.com. Its registered office is in Mumbai, Maharashtra, India.
The registered office of Bacil Pharma is at Office G2G3 Samarpan Complex Next To Mirador Hotel, Link Road Opp Satam Wadi Chakala Sahar Andheri East, Mumbai, Maharashtra, India – 400099.
Bacil Pharma has an authorised share capital of ₹20 Cr and a paid-up capital of ₹14.35 Cr.